Alembic Pharmaceuticals Ltd


1W Return


1M Return


6M Return


1Y Return


3Y Return


Start SIP in Alembic Pharmaceuticals Ltd
Stock Performance
52 Week Low - High
Today’s Low - High


Prev. Close

Total Traded Value

View details of Market Depth

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
122.52% Gain from 52W Low
TTM PE Ratio
Below industry Median
Price to Book Ratio
Below industry Median
Dividend yield 1yr %
Above industry Median
PEG TTM is less than 1
RSI is mid-range
MFI Overbought

Alembic Pharmaceuticals Ltd Key Financials

*All values are in ₹ Cr.

Alembic Pharmaceuticals Ltd Result Highlights
  • Alembic Pharma reported 2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter ended December (Q3FY24). On a year-on-year (YoY) basis, it witnessed a growth of 8%.
  • Its expenses for the quarter were down by 1% QoQ and up 8% YoY.
  • The net profit grew 32% QoQ and 48% YoY.
  • The earnings per share (EPS) of Alembic Pharma stood at 9.2 during Q3FY24.

Read More

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Alembic Pharmaceuticals Ltd shareholding Pattern

Foreign Institutions
Mutual Funds
Domestic Institutions

Alembic Pharmaceuticals Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
Bearish Moving Averages
5Day EMA
10Day EMA
12Day EMA
20Day EMA
26Day EMA
50Day EMA
100Day EMA
200Day EMA
Delivery & Volume
Resistance & Support
First Resistance
Second Resistance
Third Resistance
First Support
Second support
Third Support
Relative Strength Index
Money Flow Index
MACD Signal
Average True Range
Average Directional Index
Rate of Change (21)
Rate of Change (125)

Alembic Pharmaceuticals Ltd Company background

Founded in: 2010
Managing director: Pranav Amin
Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world. The companys state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Ltd was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business. As per the scheme of arrangement, the Pharmaceutical Undertaking of the Alembic Ltd was demerged and transferred to the company with effect from appointed date, April 1, 2010. In April 15, 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus, the company became an associate of Alembic Ltd.In September 20, 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange. During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with AccuBreak Pharmaceuticals, Inc, USA. During 2013, the company got USFDA approval for its NDA Desvenlafaxine Base Extended Release Tablets and also entered into an outlicensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. During 2014, the company announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary Alembic Global Holding S.A..During 2015, the companys associate signs exclusive agreement with Novartis. During the year, the company launched Aripiprazole on Day1. Also during the year, the company transitioned to own marketing in the US.In 2016, the company formed 60:40 joint venture with Orbicular viz. Aleor Dermaceuitical Limited for developing Dermatology Products for international markets.In July 2017, Alembic Pharmaceuticals inaugurated a state of the art anticancer manufacturing facility at Panelav, Halol, Gujarat. The plant has an initial manufacturing capacity of 60 million tablets/capsules and approximate 20 million vials of liquid injectable and lyophilized concentrates. Alembic will commence exporting oncology products from the new plant to US, Middle East, North Africa, Australia and South Africa. On 1 November 2017, Alembic Pharmaceuticals announced that through its 100% owned subsidiary, Alembic Pharmaceuticals Inc., it has completed acquisition of West Caldwell, New Jersey, USA based generic drug developer Orit Laboratories LLC along with real estate, owned by Okner Realty LLC. Orit has seven approved ANDAs and four ANDAs pending approval. With a stateoftheart 8,600 square feet RD and pilot manufacturing facility, Orit is focused on developing and filing oral solid and liquid products. Apart from existing ANDAs, Orit adds complementary skill sets in soft gelatin based oral solids and oral liquids to Alembic with a team of eight highly experienced scientists. On 21 March 2018, Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) conducted an inspection at the companys formulation facility located at Panelav, Gujarat from 12 March to 20 March 2018. This was a scheduled inspection and at the end of the inspection, the US FDA issued a Form 483 with 3 observations. None of the observations are related to data integrity or repetitive in nature. The company is preparing the response to the observations, which will be submitted to the US FDA shortly. On 24 April 2018, Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) conducted an inspection at Alembic Pharmaceuticals API Facility located at Panelav from 16 April 2018 to 23 April 2018. This was a scheduled inspection and at the end of the inspection, there were zero 483s.In 2019, the Company launched 9 new products in the US.In 2021, Rhizens outlicenced, novel molecule Umbralicib (UKONIQ) was launched by TG Therapeutics USA. During the year 202122, the Company acquired the balance 40% stake held by the joint venture partner in Aleor DermaceuticalsLimited (Aleor) and pursuant to said acquisition, Aleor became a wholly owned subsidiary of the Company.The Scheme of Arrangement for amalgamation of Aleor Dermaceuticals Limited, wholly owned subsidiary with the Company and their respective shareholders was made effective from 29th August, 2022.During FY23, the Company filed 20 ANDAs and received approvals for 22 ANDAs taking the total filed ANDAs to 245 as on March 31, 2023. At Panelav, Alembic set up dedicated blocks (F2) for manufacturing oncology products which was approved by the US FDA in 2022. The Company launched various new products, especially in the gynecology and antidiabetic spaces it launched 33 new SKUs in FY23, of which 66% were in specialty therapies. It established a subsidiary in Chile to gain a strong foothold in the large and growing Latin American markets. It opened a scientific office in the UAE to capitalise on the opportunities emerging from the GCC nations.
Read More

Alembic Pharmaceuticals Ltd FAQs

Alembic Pharmaceuticals Ltd shares are currently priced at 1028.7 on NSE and 1026.45 on BSE as of 2/27/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Alembic Pharmaceuticals Ltd [APLLTD] share was 101.19. The Alembic Pharmaceuticals Ltd [APLLTD] share hit a 1-year low of Rs. 462.3 and a 1-year high of Rs. 1094.

The market cap of Alembic Pharmaceuticals Ltd is Rs. 20220.45 Cr. as of 2/27/2024 12:00:00 AM.

The PE ratios of Alembic Pharmaceuticals Ltd is 33.9 as of 2/27/2024 12:00:00 AM.

The PB ratios of Alembic Pharmaceuticals Ltd is 4.49 as of 2/27/2024 12:00:00 AM

The Mutual Fund Shareholding was 7.71% at the end of 2/27/2024 12:00:00 AM.

You can easily buy Alembic Pharmaceuticals Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -